Buenos Aires, BUENOS%20AIRES9 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Buenos Aires, BUENOS%20AIRES

Find 9 actively recruiting myalgic encephalomyelitis clinical trials in Buenos Aires, BUENOS%20AIRES. Connect with local research sites and explore new treatment options.

9
Active Trials
8
Sponsors
3,187
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Buenos Aires

RecruitingBuenos Aires, BUENOS%20AIRESNCT05352672

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually call...

1,535 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT06054555

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma....

620 participants
Amgen
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT06577935

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mas...

350 participants
Angitia Biopharmaceuticals
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT03955445

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glo...

225 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT07087054

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with ca...

141 participants
Crinetics Pharmaceuticals Inc.
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT05334368

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study w...

123 participants
GlaxoSmithKline
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT03340506

Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-s...

100 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT05371613

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central n...

63 participants
Denali Therapeutics Inc.
View Study Details
RecruitingBuenos Aires, BUENOS%20AIRESNCT07157787

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein cr...

30 participants
Alexion Pharmaceuticals, Inc.
View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Buenos Aires

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 9 myalgic encephalomyelitis clinical trials recruiting participants in Buenos Aires, BUENOS%20AIRES. These studies are seeking a combined 3,187 participants. Research is being sponsored by Regeneron Pharmaceuticals, Amgen, Angitia Biopharmaceuticals and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Buenos Aires — FAQ

Are there myalgic encephalomyelitis clinical trials in Buenos Aires?

Yes, there are 9 myalgic encephalomyelitis clinical trials currently recruiting in Buenos Aires, BUENOS%20AIRES. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Buenos Aires?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buenos Aires research site will contact you about next steps.

Are clinical trials in Buenos Aires free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buenos Aires studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 9 active trials in Buenos Aires are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov